Amikacin in the treatment of genito-urinary tract infections in cancer patients.
Amikacin was used in the treatment of severe urinary tract infections in twenty-five seriously ill patients. In twenty-four of the patients, cystitis or pyelonephritis complicated carcinoma of the bladder. Structural changes in the urinary tract, resulting from schistosomiasis, presented additional obstacles to treatment in many of the patients. The most commonly isolated pathogens were Escherichia coli and Pseudomonas. Most patients received 500 mg of amikacin every twelve hours. Three patients experienced adverse renal reactions which showed subsequent improvement. Amikacin effected twenty-one (84%) complete cures and four (16%) clinical cures in the twenty-five patients. This represents 100% clinical success in this study.
D000328:Adult; D000368:Aged; D000583:Amikacin / Q000009:adverse effects / Q000627:therapeutic use*; D003556:Cystitis / Q000150:complications / Q000188:drug therapy*; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy; D011704:Pyelonephritis / Q000150:complications / Q000188:drug therapy*; D001749:Urinary Bladder Neoplasms / Q000150:complications*
D007612:Kanamycin; D000583:Amikacin